Log in

Relevant bibliographies by topics / Milan systemic therapy / Journal articles

To see the other types of publications on this topic, follow the link: Milan systemic therapy.

Journal articles on the topic 'Milan systemic therapy'

Author: Grafiati

Published: 4 June 2021

Last updated: 16 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 31 journal articles for your research on the topic 'Milan systemic therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Campbell, David. "Family Therapy and Beyond: Where is the Milan Systemic Approach Today?" Child Psychology and Psychiatry Review 4, no. 2 (1999): 76–84. http://dx.doi.org/10.1017/s1360641799001896.

Full text

Abstract:

This paper reviews the current position of the Milan Approach in the family therapy field. Over the past 20 years this approach has made a major contribution to the development of family therapy theory and practice in the U.K. However, the ideas have been modified in order to fit different client groups in a range of settings; until today, the Milan, or Post-Milan approach is an amalgam of the original concepts and new techniques. This paper describes the development of this approach and highlights the following topics as central to current thinking: language, power, narrative, family resilien

APA, Harvard, Vancouver, ISO, and other styles

2

Eisler, Ivan. "Applications of systemic family therapy: the Milan approach." Behaviour Research and Therapy 24, no. 6 (1986): 699–700. http://dx.doi.org/10.1016/0005-7967(86)90075-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Friedlander, Myrna L., Julie Wildman, and Laurie Heatherington. "INTERPERSONAL CONTROL IN STRUCTURAL AND MILAN SYSTEMIC FAMILY THERAPY." Journal of Marital and Family Therapy 17, no. 4 (1991): 395–408. http://dx.doi.org/10.1111/j.1752-0606.1991.tb00909.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Ruben, Douglas H. "Family systems therapy: Developments in the Milan-systemic therapies." Journal of Behavior Therapy and Experimental Psychiatry 24, no. 3 (1993): 272–73. http://dx.doi.org/10.1016/0005-7916(93)90034-t.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Carr, Alan. "Milan systemic family therapy: a review of ten empirical investigations." Journal of Family Therapy 13, no. 3 (1991): 237–63. http://dx.doi.org/10.1046/j..1991.00425.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Campbell, David. "Family Therapy and Beyond: Where is the Milan Systemic Approach Today?" Child and Adolescent Mental Health 4, no. 2 (1999): 76–84. http://dx.doi.org/10.1111/1475-3588.00254.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Kemenoff, Sylvia, Frances Worchel, Bruce Prevatt, and Victor Willson. "The effects of video feedback in the context of Milan Systemic therapy." Journal of Family Psychology 9, no. 4 (1995): 446–50. http://dx.doi.org/10.1037/0893-3200.9.4.446.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Garland, Diana S. Richmond. "Book Review: III. Ministry Studies: Applications of Systemic Family Therapy: The Milan Approach." Review & Expositor 86, no. 1 (1989): 133–34. http://dx.doi.org/10.1177/003463738908600133.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Lannamann, John W. "Communication theory applied to relational change: A case study in milan systemic family therapy." Journal of Applied Communication Research 17, no. 1-2 (1989): 71–91. http://dx.doi.org/10.1080/00909888909365285.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Tchernev, Georgi, Torello Lotti, Uwe Wollina, et al. "Sarcoidosis in A. C. Milan (1899)?" Open Access Macedonian Journal of Medical Sciences 6, no. 1 (2018): 99–102. http://dx.doi.org/10.3889/oamjms.2018.049.

Full text

Abstract:

The pathogenesis, diagnosis and therapy of sarcoidosis as an autonomous disease are subjects of spirited discussions, which haven’t found definitive conclusion yet. Distinguishing between sarcoidosis and sarcoid-like reactions (sarcoid - type granulomas) is not currently a medical “gold standard” and is not implemented in clinical practice. This leads to 1) misinterpretation of numerous available data; 2) difficulty in the interpretation of other unverified data, which is often followed by 3) inappropriate or inadequate therapeutic approach. Similarly to many other diseases, in sarcoidosis and

APA, Harvard, Vancouver, ISO, and other styles

11

Yeates, Giles N., Michael Luckie, Zach de Beer, and Parmjit Khela. "Elucidating the psychosocial context of ‘post-concussion syndrome’ (PCS): a case study from post-Milan systemic family therapy." Journal of Family Therapy 32, no. 2 (2010): 186–202. http://dx.doi.org/10.1111/j.1467-6427.2010.00493.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Sanfilippo, Roberta, Vittoria Colia, Elena Fumagalli, et al. "Sensitivity to chemotherapy of low-grade endometrial stromal sarcoma (LGESS) versus high-grade endometrial stromal sarcoma (HGESS)." Journal of Clinical Oncology 35, no. 15_suppl (2017): 11072. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.11072.

Full text

Abstract:

11072 Background: LGESS and HGESS are rare uterine neoplasms of endometrial stromal origin. The activity of hormonal therapy in LGESS is reported, whilst no data are available in HGESS. The activity of chemotherapy is unknown in both. We focused on LGESS and HGESS to explore their sensibility to chemotherapy Methods: Cases diagnosed with LGHSS and HGESS from 1997 at Istituto Nazionale Tumori, Milan, or within the Italian Rare Cancer Network (RTR), were reviewed. Results: We identified 39 patients (pts), 28 with LGESS (median age:43) and 11 (median age: 54) with HGESS. Seventeen LGESS pts recei

APA, Harvard, Vancouver, ISO, and other styles

13

Gerosa, M., G. A. Ramirez, C. Bellocchi, et al. "FRI0167 LONG TERM CLINICAL OUTCOME IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS FOLLOWED FOR MORE THAN 20 YEARS IN THREE ITALIAN TERTIARY REFERRAL CENTERS: THE MILAN SYSTEMIC LUPUS ERYTHEMATOSUS CONSORTIUM (SMILE) COHORT." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 667.1–668. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2139.

Full text

Abstract:

Background:the prognosis of Systemic lupus Erythematosus (SLE) patients has significantly improved over time, raising the need for more data about disease activity and damage accrual in the long term.Objectives:to investigate the risk of long term disease activity and to identify viable prognostic markers for disease flares in SLE patients with long standing diseaseMethods:data on SLE patients regularly followed at ASST PINI-CTO, Fondazione Ca’ Granda Policlinico and Ospedale San Raffaele, Milan (Milan Systemic Lupus Erythematosus Consortium, SMiLE, cohort) with disease duration ≥ 20 years, we

APA, Harvard, Vancouver, ISO, and other styles

14

Karageorge, A., P. Rhodes, R. Gray, and R. Papadopoulos. "Relationship and Family Therapy for Newly-resettled Refugees: A Qualitative Inquiry of an Innovative, Needs-adapted Approach in Sydney, Australia." European Psychiatry 41, S1 (2017): S622—S623. http://dx.doi.org/10.1016/j.eurpsy.2017.01.1004.

Full text

Abstract:

IntroductionThe needs of refugees are of pivotal concern internationally. Relational trauma, in particular, is an area that is under-emphasised and under-researched. The strength to strength program (STS) was a rare, innovative relationship and family counselling service for recently-arrived refugees in Sydney, Australia during 2006–2014. The service model built on post-Milan systemic family therapy principles to include innovative cultural and trauma-informed aspects of care.ObjectivesWe were interested in the experiences of staff who delivered the program, and the ways in which more traditio

APA, Harvard, Vancouver, ISO, and other styles

15

Prelaj, Arsela, Giuseppe Lo Russo, Claudia Proto, et al. "Prognostic score for second or further line immunotherapy in advanced non-small cell lung cancer (aNSCLC): An external validation." Journal of Clinical Oncology 37, no. 15_suppl (2019): e14077-e14077. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14077.

Full text

Abstract:

e14077 Background: Beyond PD-L1, nowadays oncologists can only use clinical characteristics to candidate patients for immunotherapy (IO). Previously, a clinical prognostic score composed by ECOG performance status (PS), sex, histology, stage, uses of platin-based therapy at first-line (1L) and response to 1L categorized 3 different prognostic groups for patients treated with second-line (2L) chemotherapy (CHT) (Di Maio, EJC. 2010 Mar;46(4):735-43.). The aim of this study is to assess if the same score is able to discriminate the outcome of aNSCLC pts treated in 2L or further-line IO, potential

APA, Harvard, Vancouver, ISO, and other styles

16

Mancini, Ilaria, Silvia Pontiggia, Barbara Ferrari, et al. "Natural History of Patients Affected with Thrombotic Thrombocytopenic Purpura: Milan TTP Registry." Blood 128, no. 22 (2016): 3731. http://dx.doi.org/10.1182/blood.v128.22.3731.3731.

Full text

Abstract:

Abstract Introduction: thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening thrombotic microangiopathy, with a reported incidence of 2-6 cases/million/year and a 10-20% mortality. TTP is associated with the severe deficiency of the von Willebrand factor cleaving protease, ADAMTS13, due to congenital defects in the ADAMTS13 gene (congenital TTP) or to the development of autoantibodies against ADAMTS13. The Milan TTP Registry is a digital database developed and curated at the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Po

APA, Harvard, Vancouver, ISO, and other styles

17

Colia, Vittoria, Angelo Paolo Dei Tos, Elena Fumagalli, et al. "Benign metastasizing leiomyoma (BML): A retrospective case series analysis of 8 patients (pts)." Journal of Clinical Oncology 35, no. 15_suppl (2017): e22525-e22525. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e22525.

Full text

Abstract:

e22525 Background: BML is a rare entity marked by the presence of lung lesions in women with a history of surgery for a benign leiomyoma of the uterus. Optimal treatment strategy for BML is poorly defined. We report on the activity of systemic therapy in a retrospective series of pts with BML. Methods: Cases diagnosed with BML from June 1993 to January 2017 at Istituto Nazionale Tumori, Milan, were reviewed. Results: Eight pts were identified, with a median age of 43 yrs. Estrogen and progesteron receptors were positive in all cases. All pts underwent surgery (3 hysterectomy, 2 myomectomy, 2 h

APA, Harvard, Vancouver, ISO, and other styles

18

Pastano, Rocco, Chiara Dell'Agnola, Caterina Bason, et al. "Rituximab Reduces Anti-UL94 and Anti-NAG-2 Antibodies Titer and Is Effective against Skin-Chronic Graft Versus Host Disease Resembling Scleroderma." Blood 114, no. 22 (2009): 4654. http://dx.doi.org/10.1182/blood.v114.22.4654.4654.

Full text

Abstract:

Abstract Abstract 4654 We previously described a potential pathogenetic link between human Cytomegalovirus (hCMV) infection and scleroderma-like skin chronic graft versus host disease (cGVHD) in allogeneic stem cell transplant patients (HCT), through a mechanism of molecular mimicry between UL-94 viral protein and NAG-2 molecule. Antibodies against UL-94 and NAG-2 induce apoptosis of endothelial cells and fibroblasts proliferation as observed in Systemic Sclerosis ( SSc ) patients (ASH 2009, Abstract 1169; EBMT 2009, oral comunication 377). The observation that the anti-CD20 chimaeric monoclon

APA, Harvard, Vancouver, ISO, and other styles

19

Finocchiaro, Gaetano, Bernhard Gentner, Fabio Ciceri та ін. "ATIM-36. TEM-GBM-001 STUDY: AUTOLOGOUS CD34+ ENRICHED HEMATOPOIETIC PROGENITOR CELLS GENETICALLY MODIFIED FOR HUMAN INTERFERON-α2 & ADMINISTERED TO PATIENTS WITH GLIOBLASTOMA & AN UNMETHYLATED MGMT PROMOTER". Neuro-Oncology 21, Supplement_6 (2019): vi9. http://dx.doi.org/10.1093/neuonc/noz175.035.

Full text

Abstract:

Abstract BACKGROUND Most patients with GBM & an unmethylated O-6-methylguanine-DNA methylase (MGMT) gene promoter, have a poor prognosis with approximately 20% of patients surviving to 2 years. Poor prognosis is likely related to factors including a highly immunosuppressive tumor microenvironment (TME). The TME in GBM is mainly composed of tumor associated macrophages (TAMs) & microglia. A subset of tumor-infiltrating macrophages characterized by expression of the angiopoietin receptor Tie2 (TEMs) have features of M2-TAMs, promote tumor angiogenesis & are infrequently found in norm

APA, Harvard, Vancouver, ISO, and other styles

20

Munzone, Elisabetta, Edoardo Botteri, Nicole Rotmensz, et al. "Prognostic effect of beta blockers (BB) in triple-negative breast cancer (TNBC) patients." Journal of Clinical Oncology 31, no. 15_suppl (2013): 1061. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.1061.

Full text

Abstract:

1061 Background: BB drugs have been used for decades worldwide, typically to treat hypertension and arrhythmias. Despite its therapeutic indication, evidence from recent epidemiological studies suggested that BB intake can improve prognosis of patients (pts) with cancer. With the present study we aimed at assessing whether BB intake is associated with improved prognosis in postmenopausal pts with TNBC, which represents one of the most aggressive cancers. Methods: We retrospectively identified 659 postmenopausal pts operated between 1997 and 2008 at the European Institute of Oncology, Milan, fo

APA, Harvard, Vancouver, ISO, and other styles

21

Graziadei, Giovanna, Laura Sainati, Pietro Bonomo, et al. "Transfusion Therapy in a Multi-Ethnic Sickle Cell Population Real-World Practice. a Preliminary Data Analysis of Multicentre Survey." Blood 132, Supplement 1 (2018): 2389. http://dx.doi.org/10.1182/blood-2018-99-115938.

Full text

Abstract:

Abstract Introduction. Despite the increasing of number of patients with Sickle Cell Disease (SCD) in Italy, due to multi-ethnic migratory phenomena, a large percentage of Caucasian sickle population is already present in Italy mainly with b-thal/HbS genotype. Red cell transfusion is one effective treatment for both acute and chronic complications of SCD, while hydroxycarbamide (HC) is used to reduce the frequency of painful vaso-occlusive crises (VOCs) and decrease the need for blood transfusion. Through the National Comprehensive Reference Centers for SCD, the Italian Society of Thalassemia

APA, Harvard, Vancouver, ISO, and other styles

22

Gentner, B., F. Ciceri, F. DiMeco та ін. "P05.02 A phase I/IIa dose escalation study evaluating the safety and efficacy of autologous CD34+ enriched hematopoietic progenitor cells genetically modified for human interferon-α2 in patients with GBM and an unmethylated MGMT promoter (TEM-GBM-001)". Neuro-Oncology 21, Supplement_3 (2019): iii34. http://dx.doi.org/10.1093/neuonc/noz126.116.

Full text

Abstract:

Abstract BACKGROUND Glioblastoma (GBM) remains the most common malignant primary brain tumor in adults. Most patients with GBM & an unmethylated O-6-methylguanine-DNA methylase (MGMT) gene promoter, have a poor prognosis with approximately 20% of patients surviving to 2 years. Poor prognosis is likely related to a number of factors including a highly immunosuppressive tumor microenvironment (TME). The TME in GBM is mainly composed of tumor associated macrophages (TAMs) & microglia. A subset of tumor-infiltrating macrophages characterized by expression of the angiopoietin receptor Tie2

APA, Harvard, Vancouver, ISO, and other styles

23

Gentner, Bernhard, Francesca Farina, Matteo Giovanni Carrabba та ін. "TEM-MM-101: A Phase I/IIa Dose Escalation Study Evaluating the Safety and Activity of Autologous CD34+ Enriched Hematopoietic Progenitor Cells Genetically Modified for Human Interferon-α2 in Multiple Myeloma Patients with Early Relapse after Intensive Front Line Therapy". Blood 134, Supplement_1 (2019): 2064. http://dx.doi.org/10.1182/blood-2019-123749.

Full text

Abstract:

BACKGROUND Multiple Myeloma (MM) is an incurable malignancy heralded by an immunosuppressive tumor microenvironment (TME). Therapeutic efforts to reprogram the TME and release innate and adaptive immunity may synergize with current anti-MM drugs, deepen responses and ultimately prolong long-term survival. We have developed an ex vivo gene therapy approach that locally delivers interferon-alpha (IFNa) into the TME through the Tie2+ myeloid progeny of transplanted gene-modified hematopoietic stem and progenitor cells (HSPCs). Preclinical studies in the immunocompetent Vk*Myc murine model as well

APA, Harvard, Vancouver, ISO, and other styles

24

Bridgewater, S., J. Dawson, M. Ndosi, et al. "AB0834 DEVELOPMENT OF A CONCEPTUAL FRAMEWORK FOR A PATIENT REPORTED OUTCOME MEASURE TO CAPTURE PATIENTS’ PERCEPTIONS OF GLUCOCORTICOID THERAPY DURING TREATMENT FOR RHEUMATIC DISEASES." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1441.1–1441. http://dx.doi.org/10.1136/annrheumdis-2021-eular.164.

Full text

Abstract:

Background:Glucocorticoids (GCs) are a key treatment for the autoimmune rheumatic diseases; however, they produce numerous physical and psychological side effects.1 The Outcome Measures in Rheumatology (OMERACT) Glucocorticoid Working Group have identified that there are no Patient Reported Outcome Measures (PROMs) for assessing the impact of systemic GC therapy across multiple rheumatic diseases from the patient’s perspective.2,3Objectives:The aim is to explore the impact of GCs on the symptoms and health-related quality of life of adults with rheumatic inflammatory diseases, to inform items

APA, Harvard, Vancouver, ISO, and other styles

25

Milani, Paolo, Vaishali Sanchorawala, Ramon Lecumberri, et al. "Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey." Blood 136, Supplement 1 (2020): 11. http://dx.doi.org/10.1182/blood-2020-141569.

Full text

Abstract:

Introduction: The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has become a global health crisis since it was first reported in December 2019. In a subset of infected subjects, pneumonia, multi-organ failure, and eventually death can occur. Frail patients and those with comorbidities are believed to be at increased risk of severe manifestations of SARS-CoV-2 infection. Patients with light chain (AL) amyloidosis have a hematologic malignancy that causes multi-organ dysfunction and can be at higher risk of complications and death. The International Society of Amyloidosis (ISA) has issued a

APA, Harvard, Vancouver, ISO, and other styles

26

Nadarajah, R. N. Sugitha. "Combating cancer one step at a time." Advances in Modern Oncology Research 2, no. 5 (2016): 244. http://dx.doi.org/10.18282/amor.v2.i5.179.

Full text

Abstract:

<p>"I graduated from the Faculty of Medicine at Ain Shams University,” says the oncologist, who completed his Bachelor of Medicine and Surgery in 2005 and is now working at the same university as a lecturer in clinical oncology. Ain Shams University, originally known as ‘Ibrahim Pasha’s University’ prides itself in being the third higher education institution to be founded in Egypt. It has produced famous alumni that include current acting Egyptian Prime Minister Sherif Ismail Mohamed and former Egyptian Prime Minister Abd El Aziz Muhammad Hegazi, as well as the noted American modern phi

APA, Harvard, Vancouver, ISO, and other styles

27

Preziati, Daniela, Luigi La Rosa, Giovanni Covini, et al. "Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a." European Journal of Endocrinology 132, no. 5 (1995): 587–93. http://dx.doi.org/10.1530/eje.0.1320587.

Full text

Abstract:

Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, Del Ninno E, Meroni PL, Colombo M, Beck-Peccoz P. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995;132:587–93. ISSN 0804–4643 The occurrence of thyroid abnormalities and the appearance of organ- and non-organ-specific autoantibodies during long-term recombinant interferon alpha-2a (IFN-α) therapy were studied in 86 and 51 consecutive outpatients with hepatitis C and B virus-related chronic active hepatitis (CAH-HCV and CAH-HBV), resp

APA, Harvard, Vancouver, ISO, and other styles

28

Masood, Adeel, Moazzam Shahzad, Ahsan Wahab, et al. "Management of light chain deposition disease: A systematic review." Journal of Clinical Oncology 39, no. 15_suppl (2021): e20042-e20042. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e20042.

Full text

Abstract:

e20042 Background: Light-chain deposition disease (LCDD) is part of a wide spectrum of plasma cell proliferation disorders. LCDD predominantly affects kidneys by systemic deposition of congo red negative non-fibrillar light chains. Due to the rarity of disease, no prospective data is available, and clear guidelines don’t exist for the treatment. We reviewed data to summarize effective treatment strategies. Methods: A literature search was conducted on PubMed, Cochrane, and ClinicalTrials.gov with final update in November 2020 using terms ‘light chain deposition disease’, ‘therapy,’ and ‘diseas

APA, Harvard, Vancouver, ISO, and other styles

29

Sarosiek, Shayna, Vaishali Sanchorawala, Mariateresa Fulcinti, Allison P. Jacob, Nikhil C. Munshi, and Cindy Varga. "The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study." Blood 134, Supplement_1 (2019): 4353. http://dx.doi.org/10.1182/blood-2019-131863.

Full text

Abstract:

Background: AL amyloidosis is a bone marrow disorder in which clonal plasma cells produce light chains that misfold and deposit in vital organs, such as the kidneys and heart, leading to organ failure and eventual death. Treatment is directed towards the clonal plasma cell population in an effort to halt the production of toxic light chains and recuperate organ function. Pallidini et al. demonstrated that almost 50% of patients with AL amyloidosis who achieved a complete hematologic response to prior therapy had minimal residual disease (MRD) detectable in their bone marrow by multiparametric

APA, Harvard, Vancouver, ISO, and other styles

30

Opat, Stephen, Alessandra Tedeschi, Kim Linton, et al. "Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial." Blood 136, Supplement 1 (2020): 28–30. http://dx.doi.org/10.1182/blood-2020-134611.

Full text

Abstract:

Background: Marginal zone lymphoma (MZL) is rare and heterogeneous and it has been difficult to define optimal therapeutic strategies. Like other indolent non-Hodgkin lymphomas, advanced stage disease is considered incurable, with most patients experiencing a continuing pattern of relapse and remission. MZL is typically dependent on B-cell receptor (BCR) signaling suggesting a role for BCR pathway targeting via inhibition of Bruton's tyrosine kinase (BTK). The utility of this approach was confirmed by the pivotal phase 2 study demonstrating a 48% objective response rate (ORR) to ibrutinib in p

APA, Harvard, Vancouver, ISO, and other styles

31

Callejas-Moraga, Eduardo Luis, Alfredo Guillén-Del-Castillo, Janire Perurena-Prieto, et al. "Anti-RNPC-3 antibody predicts poor prognosis in patients with interstitial lung disease associated to systemic sclerosis." Rheumatology, March 20, 2021. http://dx.doi.org/10.1093/rheumatology/keab279.

Full text

Abstract:

Abstract Objective To analyse the prevalence, the clinical characteristics, the overall survival and the event-free survival (EFS) of SSc patients who express anti-U11/U12 RNP (RNPC-3) antibodies. Methods A total of 447 SSc patients from Barcelona (n = 286) and Milan (n = 161) were selected. All samples were tested using a particle-based multi-analyte technology. We compared anti-RNPC-3 positive and negative patients. Epidemiological, clinical features and survival were analysed. End-stage lung disease (ESLD) was defined if the patient developed forced vital capacity &lt;50% of predicted,

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!